Intrafamilial correlation of clinical manifestations in neurofibromatosis 2 (NF2)

Genetic Epidemiology

Volumn 23, Issue 3, 2002, Pages 245-259

  Zhao, Y ^a   Kumar, R A ^a   Baser, M E ^b   Evans, D G R ^c   Wallace, A ^c   Kluwe, L ^c   Mautner, V F ^d   Parry, D M ^e   Rouleau, G A ^a   Joe, H ^a   Friedman, J M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b St Mary's Hospital ^*

^c Klinik Ochsenzoll   (Germany)

^d NATIONAL CANCER INSTITUTE   (United States)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

Intrafamilial correlation; Negative binomial gamma mixture model; Neurofibromatosis 2; Random effects model; Right censoring

Indexed keywords

ADULT; ALLELISM; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BINOMIAL DISTRIBUTION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; EPIDEMIOLOGICAL DATA; FAMILIAL DISEASE; GENE MUTATION; GENETIC VARIABILITY; HEARING LOSS; HUMAN; MAJOR CLINICAL STUDY; MENINGIOMA; MISSENSE MUTATION; NEUROFIBROMATOSIS; ONSET AGE; STATISTICAL MODEL; TUMOR SUPPRESSOR GENE; VARIANCE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, NEUROFIBROMATOSIS 2; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; INFANT; LIKELIHOOD FUNCTIONS; MALE; MIDDLE AGED; MODELS, GENETIC; MODELS, STATISTICAL; NEUROFIBROMATOSIS 2; PHENOTYPE;

EID: 18644371170     PISSN: 07410395     EISSN: None     Source Type: Journal    
DOI: 10.1002/gepi.10181     Document Type: Article

References (47)

1. Agresti A. 1990. Categorical data analysis. New York: John Wiley and Sons.
2. Baser ME, Mautner VF, Ragge NK, Nechiporuk A, Riccardi VM, Klein J, Sainz J, Pulst SM. 1996a. Presymptomatic diagnosis of neurofibromatosis 2 using linked genetic markers, neuroimaging, and ocular examinations. Neurology 47:1269-77.
3. Baser ME, Ragge NK, Riccardi VM, Janus T, Gantz B, Pulst SM. 1996b. Phenotypic variability in monozygotic twins with neurofibromatosis 2. Am J Med Genet 64:563-7.
4. Bijlsma EK, Merel P, Fleury P, van Asperen CJ, Westerveld A, Delattre O, Thomas G, Hulsebos TJ. 1995. Family with neurofibromatosis type 2 and autosomal dominant hearing loss: identification of carriers of the mutated NF2 gene. Hum Genet 96:1-5.
5. Bruder CE, Ichimura K, Blennow E, Ikeuchi T, Yamaguchi T, Yuasa Y, Collins VP, Dumanski JP. 1999. Severe phenotype of neurofibromatosis type 2 in a patient with a 7.4-MB constitutional deletion on chromosome 22: possible localization of a neurofibromatosis type 2 modifier gene? Genes Chromosomes Cancer 25:184-90.
6. Bruder CE, Hirvela C, Tapia-Paez I, Fransson I, Segraves R, Hamilton G, Zhang XX, Evans DG, Wallace AJ, Baser ME, Zucman-Rossi J, Hergersberg M, Boltshauser E, Papi L, Rouleau GA, Poptodorov G, Jordanova A, Rask-Andersen H, Kluwe L, Mautner V, Sainio U, Hung G, Mathiesen T, Moller C, Pulst SM, Harder H, Heiberg A, Honda M, Niimura M, Sahlen S, Blennow E, Albertson DG, Pinkel D, Dumanski JP. 2001. High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH. Hum Mol Genet 10:271-82.
7. Comtesse N, Heckel D, Racz A, Brass N, Glass B, Meese E. 1999. Five novel immunogenic antigens in meningioma: cloning, expression analysis, and chromosomal mapping. Clin Cancer Res 5:3560-8.
8. De Klein A, Riegman PH, Bijlsma EK, Heldoorn A, Muijtjens M, den Bakker MA, Avezaat CJ, Zwarthoff EC. 1998. A G→A transition creates a branch point sequence and activation of a cryptic exon, resulting in the hereditary disorder neurofibromatosis 2. Hum Mol Genet 7:393-398.
9. Dipple KM, McCabe RB. 2000. Phenotypes of patients with "simple" mendelian disorders are complex traits: thresholds, modifiers, and systems dynamics. Am J Hum Genet 66:1729-1735.
10. Evans DG, Huson SM, Donnai D, Neary W, Blair V, Teare D, Newton V, Strachan T, Ramsden R, Harris R. 1992a. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 29:841-6.
11. Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, Strachan T, Harris R. 1992b. A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling. J Med Genet 29:847-52.
12. Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, Harris R. 1992c. A clinical study of type 2 neurofibromatosis. Q J Med 84:603-18.
13. Evans DG, Trueman L, Wallace A, Collins S, Strachan T. 1998a. Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet 35:450-5.
14. Evans DG, Wallace AJ, Wu CL, Trueman L, Ramsden RT, Strachan T. 1998b. Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis. Am J Hum Genet 63:727-36.
15. Evans DG, Sainio M, Baser ME. 2000. Neurofibromatosis type 2. J Med Genet 37:897-904.
16. Foulley JL, Gianola D, Im S. 1987. Genetic evaluation of traits distributed as Poisson-binomial with reference to reproductive characters. Theor Appl Genet 73:870-7.
17. Goutebroze L, Brault E, Muchardt C, Camonis J, Thomas G. 2000. Cloning and characterization of SCHIP-1, a novel protein interacting specifically with spliced isoforms and naturally occurring mutant NF2 proteins. Mol Cell Biol 20:1699-712.
18. Hung G, Faudoa R, Baser ME, Xue Z, Kluwe L, Slattery W, Brackman D, Lim D. 2000. Neurofibromatosis 2 phenotypes and germ-line NF2 mutations determined by an RNA mismatch method and loss of heterozygosity analysis in NF2 schwannomas. Cancer Genet Cytogenet 118:167-8.
19. Jacoby LB, MacCollin M, Parry DM, Kluwe L, Lynch J, Jones D. 1999. Allelic expression of the NF2 gene in neurofibromtosis 2 and schwannomatosis. Neurogenetics 2:101-8.
20. Jobson JD. 1996. Applied multivariate data analysis. New York: Springer-Verlag.
21. Kluwe L, Bayer S, Baser ME, Hazim W, Haase W, Funsterer C, Mautner VF. 1996. Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes. Hum Genet 98:534-8.
22. Kluwe L, MacCollin M, Tatagiba M, Thomas S, Hazim W, Haase W, Mautner VF. 1998. Phenotypic variability associated with 14 splice-site mutations in the NF2 gene. Am J Med Genet 77:228-33.
23. Lawless JF. 1987. Negative binomial and mixed Poisson regression. Can J Stat 15:209-25.
24. Lopez-Correa C, Zucman-Rossi J, Brems H, Thomas G, Legius E. 2000. NF2 gene deletion in a family with a mild phenotype. J Med Genet 37:75-7.
25. MacCollin M. 1999. Neurofibromatosis, phenotype, natural history, and pathogenesis, 3rd ed. Baltimore and London: Johns Hopkins University Press.
26. MacCollin M, Mautner VF. 1998. The diagnosis and management of neurofibromatosis 2 in childhood. Semin Pediatr Neurol 5:243-52.
27. MacCollin M, Mohney T, Trofatter J, Wertelecki W, Ramesh V, Gusella J. 1993. DNA diagnosis of neurofibromatosis 2. Altered coding sequence of the merlin tumor suppressor in an extended pedigree. JAMA 270:2316-20.
28. Mautner VF, Tatagiba M, Guthoff R, Samii M, Pulst SM. 1993. Neurofibromatosis 2 in the pediatric age group. Neurosurgery 33:92-6.
29. Mautner V, Baser M, Kluwe L. 1996. Phenotypic variability in two families with novel splice-site and frameshift NF2 mutations. Hum Genet 98:203-6.
30. Merel P, Hoang-Xuan K, Sanson M, Bijlsma E, Rouleau G, Laurent-Puig P, Pulst S, Baser M, Lenoir G, Sterkers JM, Philippon J, Resche F, Mautner VF, Fischer G, Hulsebos T, Aurias A, Delattre O, Thomas G. 1995. Screening for germ-line mutations in the NF2 gene. Genes Chromosomes Cancer 12:117-27.
31. Nash JC. 1990. Compact numerical methods for computers: linear algebra and function minimisation, 2nd ed. New York: Hilger.
32. Parry DM, Elridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N. 1994. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 52:450-46.
33. Parry DM, MacCollin MM, Kaiser-Kupfer MI, Pulaski K, Nicholson HS, Bolesta M, Eldridge R, Gusella JF. 1996. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet 59:529-39.
34. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, Hoang-Xuan K, Demczuk S, Desmaze C, Plougastel B, Pulst SM, Lenoir G, Blusma E, Fashold R, Dumanski J, de Jong P, Parry D, Eldrige R, Aurias A, Delattre O, Thomas G. 1993. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 363:515-21.
35. Ruttledge MH, Andermann AA, Phelan CM, Claudio JO, Han FY, Chretien N, Rangaratnam S, MacCollin M, Short P, Parry D, Vichels V, Riccardi VM, Weksburg R, Kitamura K, Bradburn JM, Hall BD, Propping P, Rouleau GA. 1996. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet 59:331-42.
36. Sainio M, Strachan T, Blomstedt G, Salonen O, Setala K, Palotie A, Palo J, Pyyko I, Peltonen L, Jaaskelainen J. 1995. Presymptomatic DNA and MRI diagnosis of neurofibromatosis 2 with mild clinical course in an extended pedigree. Neurology 45:1314-22.
37. Sainio M, Jaaskelainen J, Pihlaja H, Carpen O. 2000. Mild familial neurofibromatosis 2 associates with expression of merlin with altered COOH-terminus. Neurology 54:1132-8.
38. Sanson M, Marineau C, Desmaze C, Lutchman M, Ruttledge M, Baron C, Narod S, Delattre O, Lenoir G, Thomas G, Aurias A, Rouleau GA. 1993. Germline deletion in a neurofibromatosis type 2 kindred inactivates the NF2 gene and a candidate meningioma locus. Hum Mol Genet 8:1215-20.
39. Scoles DR, Baser ME, Pulst SM. 1996. A missense mutation in the neurofibromatosis 2 gene occurs in patients with mild and severe phenotypes. Neurology 47:544-6.
40. Scriver CR, Waters PJ. 1999. Monogenic traits are not simple: lessons from phenylketonuria. Trends Genet 15:267-72.
41. Searle SR, Casella G, McCulloch CE. 1992. Variance components. New York: John Wiley and Sons.
42. Seber G. 1977. Linear regression analysis. New York: John Wiley and Sons.
43. Sulman EP, Dumanski JP, White PS, Zhao H, Maris JM, Mathiesen T, Bruder C, Cnaan A, Brodeur GM. 1998. Identification of a consistent region of allelic loss on 1p32 in meningiomas: correlation with increased morbidity. Cancer Res 58:3226-30.
44. Tempelman RJ, Gianola D. 1996. A mixed effects model for overdispersed count data in animal breeding. Biometrics 52:265-79.
45. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K, Haase VH, Ambrose CM, Munroe D, Bove C, Haines JL, Martuza RL, MacDonald ME, Seizinger BR, Short MP, Buckler AJ, Gusella JF. 1993. A novel Moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72:791-800 [published erratum appears in Cell 1993;75:826].
46. Wertelecki W, Rouleau GA, Superneau DW, Forehand LW, Williams JP, Haines JL, Gusella JF. 1988. Neurofibromatosis 2: clinical and DNA linkage studies of a large kindred. N Engl J Med 319: 278-83.
47. Zucman-Rossi J, Legoix P, Der Sarkissian H, Cheret G, Sor F, Bernardi A, Cazes A, Giraud S, Ollagnon E, Lenoir G, Thomas G. 1998. NF2 gene in neurofibromatosis type 2 patients. Hum Mol Genet 7:2095-101.